Dupilumab‐induced phenotype switch from atopic dermatitis to psoriasis is characterized by de novo interleukin‐17A expression: a case report

F.N. Mirza,A. Wang,S.M. Ramachandran,W. Damsky,J.M. Cohen
DOI: https://doi.org/10.1111/bjd.20064
IF: 11.113
2021-05-04
British Journal of Dermatology
Abstract:Psoriasis and atopic dermatitis are chronic T‐cell mediated inflammatory diseases that are thought to exist on a polar Th1/17‐to‐Th2 spectrum.1 Psoriasis is associated with overproduction of IL‐17A/F, IL‐23 (Th17), and IL‐12 (Th1). A Th2 polarized response with overproduction of IL‐13 and IL‐4 is typical of atopic dermatitis.1 Dupilumab, a monoclonal antibody that inhibits both IL‐13 and IL‐4 is effective in atopic dermatitis.2 Since its 2017 US Food and Drug Administration approval for this indication, case reports have suggested that dupilumab may lead to development of psoriasis.
dermatology
What problem does this paper attempt to address?